SEC Form 4 · accession 0001140361-26-029331

ANGIODYNAMICS INC · ANGO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP/GM, Vascular Access

Period of report

Jul 15, 2026

Accepted (ET)

Jul 22, 2026 · 8:06 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001275187

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jul 15, 2026	A	16,081	$0.00	A	104,540	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Performance Right^F2	—	Jul 15, 2026	A	16,081	A	—	—	Common Stock	16,081	16,081	D

F1The acquisition of 16,081 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 16,081 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.
F2Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.